In addition to conventional chemotherapeutic drugs, several agents targeting the molecular drivers of CRC pathogenesis, including signalling pathways mediated by epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), have been widely administered to patients with mCRC, with the result being increasing survival rates [6–8]. Here, VEGFA is linked to colorectal carcinoma.